Table 2 Mean IADL and PSMS scores for all patients and the sub-sample who had NARTIQ scores at baseline (week 0) and after 26, 52 and 78 weeks of cholinesterase inhibitor treatment; higher scores indicate greater dependency
Assessment | N All patients | Mean | Standard deviation | N Patients with NARTIQ | Mean | Standard deviation |
|---|---|---|---|---|---|---|
IADL(0) | 551 | 15.8 | 6.5 | 294 | 14.7 | 6.2 |
PSMS(0) | 548 | 7.9 | 3.1 | 292 | 7.5 | 2.9 |
IADL(26) | 238 | 17.3 | 5.9 | 146 | 16.9 | 5.9 |
PSMS(26) | 237 | 8.5 | 3.0 | 146 | 8.3 | 2.8 |
IADL(52) | 75 | 16.5 | 7.2 | 59 | 16.7 | 7.1 |
PSMS(52) | 74 | 8.1 | 3.5 | 58 | 8.1 | 3.4 |
IADL(78) | 46 | 18.0 | 6.1 | 39 | 18.0 | 6.5 |
PSMS(78) | 46 | 8.5 | 2.7 | 39 | 8.4 | 2.8 |